17 Mar 2021 15:30
SMITH & NEPHEW PLC
Â
17 March 2021
Â
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
Â
Following the announcement on 9 March 2021, regarding the awards made under the Smith & Nephew Global Share Plan 2020 of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company"), those share awards vested on 16 March 2021.
Â
1. FINAL VESTING ON 16 MARCH 2021 OF SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2018 PERFORMANCE SHARE PROGRAMME AWARDS:Â
Â
The awards were granted under the Global Share Plan 2020 on 8 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.
Â
The following relates to all individuals included in the below notification:
Â
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument  | Smith & Nephew plc ordinary shares of USD 0.20 each  |
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Final vesting on 16 March 2021 of Supplementary Awards granted under the Smith & Nephew Global Share Plan 2020 for the 2018 Performance Share Programme awards. |
Date of Transaction | 2021 - 03 - 16 |
Place of Transaction | London Stock Exchange (XLON) |
Â
Name (Position) | Status | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | 14.0000 Â | 3,740 (of which 1,665 were sold and 2,075 retained) | N/A Single Transaction | 84,165.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00951% Â |
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | 14.0000 Â | 1,781 (of which 841 were sold and 940 retained) | N/A Single Transaction | 45,298.19975 ordinary shares | 0.00512% Â |
Elga Lohler (Chief HR Officer) | PDMR | 14.0000 Â | 2,848 (of which 1,125 were sold and 1,723 retained) | N/A Single Transaction | 106,816.00000 ordinary shares (including 3,015.00000 in ADS') | 0.01207% Â |
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | 14.0000 Â | 2,823 (of which 963 were sold and 1,860 retained) | N/A Single Transaction | 81,517.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00921% Â |
Vasant Padmanabhan (President Research & Development) | PDMR | 14.0000 Â | 3,207 (of which 1,089 were sold and 2,118 retained) | N/A Single Transaction | 64,620.00000 ordinary shares | 0.00730% Â |
Susan Swabey (Company Secretary) | PDMR | 14.0000 Â | 1,255 (of which 592 were sold and 663 retained) | N/A Single Transaction | 49,225.83952 ordinary shares | 0.00556% Â |
Â
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
Â
Vickie Reuben
Deputy Company Secretary
Smith & Nephew plc
Â
Tel: +44 (0)1923 477410
Â